Von Willebrand disease type 3

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Nov 2022Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Bleeding and Clotting Disorders Institute Peoria, Illinois — PHASE1

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

2 programs

FINANCIAL LANDSCAPE SUMMARY

2

Total programs

2

Open now

Patient Assistance Programs2

Wilate

Octapharma USA, Inc.

OpenContact for details

Vonvendi

Takeda Pharmaceuticals U.S.A., Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

2 FDA-approved

Wilate

(von Willebrand Factor/Coagulation Factor VIII Complex (Human))Orphan drugstandard

Octapharma USA, Inc.

Vonvendi

(von Willebrand factor (recombinant))Orphan drugstandard

Takeda Pharmaceuticals U.S.A., Inc.

View full treatment details on disease page →

Clinical Trial Landscape

1 active trial
1Phase 1
1Total recruiting
Search clinical trials for Von Willebrand disease type 3

Recent News & Research

No recent news articles indexed yet for Von Willebrand disease type 3.
Search PubMed for Von Willebrand disease type 3

Browse all Von Willebrand disease type 3 news →

Specialist Network

Top 6 by expertise

View all Von Willebrand disease type 3 specialists →

Quick Actions